Emerging pharmacotherapy of tinnitus

Expert Opinion on Emerging Drugs

Volumn 16, Issue 4, 2011, Pages 603-606

  Langguth, Berthold ^a   Elgoyhen, Ana Belén ^b,c  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Animal models; Anticonvulsants; Antidepressants; Anxiolytics; Auditory system; GABA; Glutamate; Hearing; Inner ear; NMDA; Pain; Phantom perception; Randomized clinical trials

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; AM 101; AMPA RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIDIURETIC AGENT; ANTIHISTAMINIC AGENT; ANXIOLYTIC AGENT; BCG 492A; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CILOSTAZOL; CLONAZEPAM; DEXAMETHASONE; FLINDOKALNER; FLUPENTIXOL; GABAPENTIN; MELITRACEN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NERAMEXANE; NEUROLEPTIC AGENT; OTO 104; PAROXETINE; PLACEBO; SODIUM CHANNEL BLOCKING AGENT; TAURINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VESTIPITANT; VIGABATRIN;

ACUTE DISEASE; ADJUVANT THERAPY; ANXIETY DISORDER; AUDITORY NERVOUS SYSTEM; CHRONIC DISEASE; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DEPRESSION; DRUG APPROVAL; DRUG INDUSTRY; DRUG TARGETING; EPILEPSY; FOOD AND DRUG ADMINISTRATION; GABAERGIC TRANSMISSION; HUMAN; MIGRAINE; NERVE CELL PLASTICITY; NEUROCHEMISTRY; NEUROPATHIC PAIN; NONHUMAN; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SLEEP DISORDER; TINNITUS;

ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; HUMANS; TINNITUS; TREATMENT OUTCOME;

EID: 84555191744     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2011.644273     Document Type: Review

References (23)

1. Shargorodsky J, Curhan GC, Farwell WR. Prevalence and characteristics of tinnitus among US adults. Am J Med 2010;123(8):711-18
2. Langguth B. A review of tinnitus symptoms beyond 'ringing in the ears': a call to action. Curr Med Res Opin 2011;27(8):1635-43
3. Langguth B, Salvi R, Elgoyhen AB. Emerging pharmacotherapy of tinnitus. Expert Opin Emerg Drugs 2009;14(4):687-702
4. Roberts LE, Eggermont JJ, Caspary DM, et al. Ringing ears: the neuroscience of tinnitus. J Neurosci 2010;30(45):14972-9
5. Yang S, Weiner BD, Zhang LS, et al. Homeostatic plasticity drives tinnitus perception in an animal model. Proc Natl Acad Sci USA 2011;108(36):14974-9
6. Rauschecker JP, Leaver AM, Muhlau M. Tuning out the noise: limbic-auditory interactions in tinnitus. Neuron 2010;66(6):819-26
7. De Ridder D, Elgoyhen AB, Romo R, Langguth B. Phantom percepts: Tinnitus and pain as persisting aversive memory networks. Proc Natl Acad Sci USA 2011;108(20):8075-80
8. Wang H, Brozoski TJ, Caspary DM. Inhibitory neurotransmission in animal models of tinnitus: maladaptive plasticity. Hear Res 2011;279(1-2):111-17
9. Landgrebe M, Zeman F, Koller M, et al. The Tinnitus Research Initiative (TRI) database: a new approach for delineation of tinnitus subtypes and generation of predictors for treatment outcome. BMC Med Inform Decis Mak 2010;10:42
10. Middleton JW, Kiritani T, Pedersen C, et al. Mice with behavioral evidence of tinnitus exhibit dorsal cochlear nucleus hyperactivity because of decreased GABAergic inhibition. Proc Natl Acad Sci USA 2011;108(18):7601-6
11. Brozoski TJ, Caspary DM, Bauer CA, Richardson BD. The effect of SUPPL.emental dietary taurine on tinnitus and auditory discrimination in an animal model. Hear Res 2010;270(1-2):71-80
12. Zhao Y, Tzounopoulos T. Physiological activation of cholinergic inputs controls associative synaptic plasticity via modulation of endocannabinoid signaling. J Neurosci 2011;31(9):3158-68
13. Zheng Y, Stiles L, Hamilton E, et al. The effects of the synthetic cannabinoid receptor agonists, WIN55,212-2 and CP55,940, on salicylate-induced tinnitus in rats. Hear Res 2010;268(1-2):145-50
14. Lobarinas E, by-Brown W, Stolzberg D, et al. Effects of the potassium ion channel modulators BMS-204352 Maxipost and its R-enantiomer on salicylate-induced tinnitus in rats. Physiol Behav 2011;104(5):873-9
15. Piu F, Wang X, Fernandez R, et al. OTO-104: a sustained-release dexamethasone hydrogel for the treatment of otic disorders. Otol Neurotol 2011;32(1):171-9
16. Roberts C, Inamdar A, Koch A, et al. A randomized, controlled study comparing the effects of vestipitant or vestipitant and paroxetine combination in subjects with tinnitus. Otol Neurotol 2011;32(5):721-7
17. Suckfuell M, Althaus M, Ellers-Lenz B, et al. A randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of neramexane in patients with moderate to severe subjective tinnitus. BMC Ear Nose Throat Disord 2011;11(1):1
18. Neramexane: Clin Trial. Available from: http://clinicaltrials.gov/ct2/ show/NCT00739635, http://clinicaltrials.gov/ct2/show/NCT00772980, http://clinicaltrials. gov/ct2/show/NCT00827008 2011
19. BGG492A Clin Trial. Available from: http://clinicaltrials.gov/ct2/show/ NCT01302873. 2011
20. Cilostazol Clin Trial. Available from: http://clinicaltrials.gov/ct2/ show/NCT01378650. 2011
21. Meeus O, De RD, Van de HP. Administration of the combination clonazepam-Deanxit as treatment for tinnitus. Otol Neurotol 2011;32(4):701-9
22. Muehlmeier G, Biesinger E, Maier H. Safety of Intratympanic Injection of AM-101 in Patients with Acute Inner Ear Tinnitus. Audiol Neurootol 2011;16(6):388-97
23. NST001 Clin Trial. Available from: http://clinicaltrials.gov/ct2/show/ NCT00957788 2011